METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to fight spread of prostate cancer
Disease control Recruiting nowThis early-phase trial is testing a new immunotherapy drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and tolerability, while also looking …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy aims to shrink prostate cancer tumors
Disease control Recruiting nowThis study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard ca…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could drug holidays ease fatigue in prostate cancer? new trial investigates
Disease control Recruiting nowThis study tests if men with metastatic hormone-sensitive prostate cancer who have a strong initial response to hormone therapy can safely take breaks from one of their medications (relugolix) to reduce fatigue. About 160 participants will either continue standard daily therapy o…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy tracked in german men with spread prostate cancer
Disease control Recruiting nowThis study follows 500 men in Germany with metastatic hormone-sensitive prostate cancer (mHSPC) who are taking darolutamide plus standard hormone therapy. Researchers will check how many have very low PSA levels after 12 months and track survival and health over 5 years. The goal…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New prostate cancer pill could rival current standard treatment
Disease control Recruiting nowThis Phase 3 trial compares a new oral drug, rezvilutamide, against the current standard enzalutamide, both combined with hormone therapy, in 206 men with low-volume metastatic prostate cancer that still responds to hormones. The main goal is to see if rezvilutamide can lower PSA…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New trial combines drugs with surgery or radiation to fight advanced prostate cancer
Disease control Recruiting nowThis Italian study is testing whether adding local treatment (radiotherapy or surgery) to standard apalutamide and hormone therapy can delay cancer progression in men with metastatic hormone-sensitive prostate cancer. About 566 participants will first receive drug therapy for 6 m…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: NA • Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Disease control
Last updated Jun 26, 2026 13:15 UTC
-
Real-World data sought on triple therapy for Low-Volume prostate cancer
Knowledge-focused Recruiting nowThis observational study will follow 100 Japanese men with low-volume metastatic hormone-sensitive prostate cancer who are receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will collect medical records to see how many men achieve very low PSA leve…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study tracks brain and energy side effects of prostate cancer meds
Knowledge-focused Recruiting nowThis study follows 102 men with metastatic hormone-sensitive prostate cancer who are taking standard drugs (abiraterone, apalutamide, enzalutamide, or darolutamide) plus hormone therapy. Researchers will check thinking skills, fatigue, mood, and sleep at the start, 3 months, and …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
5,000 men with advanced prostate cancer to be tracked in new registry study
Knowledge-focused Recruiting nowThis study is a registry that will follow about 5,000 men with prostate cancer that has come back or spread. It aims to record which treatments doctors actually use in routine care and how the disease progresses over time. Participants are grouped by their cancer stage, from PSA …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC